Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Leukemia, Myeloid, Acute 69Breast Neoplasms 52Carcinoma, Non-Small-Cell Lung 28Neoplasms 27Myelodysplastic Syndromes 27Advanced Solid Tumors 27Advanced Solid Tumor 26Prostatic Neoplasms 24Stomach Neoplasms 19Recurrence 18Multiple Myeloma 18Carcinoma, Hepatocellular 18Neoplasm Metastasis 17Ovarian Neoplasms 15Lung Neoplasms 15Pancreatic Neoplasms 14Uterine Cervical Neoplasms 13Solid Tumor 13Sarcoma 13Melanoma 13Leukemia, Myelomonocytic, Chronic 13Colorectal Neoplasms 11Triple Negative Breast Neoplasms 10Small Cell Lung Carcinoma 10Lymphoma, Large B-Cell, Diffuse 10Squamous Cell Carcinoma of Head and Neck 8Myeloproliferative Disorders 8Lymphoma, Non-Hodgkin 8Esophageal Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7

Interventions

Trastuzumab 33pertuzumab 18Docetaxel 16pyrotinib 15Paclitaxel 7Capecitabine 6tucatinib 5Carboplatin 5Ado-Trastuzumab Emtansine 4trastuzumab deruxtecan 3neratinib 3atezolizumab 2Protons 2Fulvestrant 2pegfilgrastim 1palbociclib 1margetuximab 1liposomal doxorubicin 1inavolisib 1exemestane 1envafolimab 1dalpiciclib 1Taxoids 1Neoadjuvant Therapy 1Metformin 1Leuprolide 1Letrozole 1Isovaleryl-CoA Dehydrogenase 1Injections 1Hospital Information Systems 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2-positive Breast Cancer × Injections × Clear all
NCT07043725 2026-03-27

A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Recruiting
544 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡